BCTX
NASDAQ · Biotechnology
Briacell Therapeutics Corp
$4.13
+0.38 (+10.13%)
Financial Highlights (FY 2025)
Revenue
6.36M
Net Income
-563,828
Gross Margin
61.5%
Profit Margin
-8.9%
Rev Growth
-7.7%
D/E Ratio
0.28
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 61.5% | 61.5% | 61.5% |
| Operating Margin | -7.3% | -7.7% | -6.6% |
| Profit Margin | -8.9% | -8.8% | -8.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.36M | 5.82M | 6.86M |
| Gross Profit | 3.92M | 3.58M | 4.22M |
| Operating Income | -465,848 | -449,691 | -456,137 |
| Net Income | -563,828 | -513,311 | -545,732 |
| Gross Margin | 61.5% | 61.5% | 61.5% |
| Operating Margin | -7.3% | -7.7% | -6.6% |
| Profit Margin | -8.9% | -8.8% | -8.0% |
| Rev Growth | -7.7% | -7.5% | +13.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 7.64M | 8.28M | 7.68M |
| Total Equity | 27.12M | 27.65M | 30.75M |
| D/E Ratio | 0.28 | 0.30 | 0.25 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -665,396 | -604,117 | -725,268 |
| Free Cash Flow | -534,078 | -494,442 | -500,696 |